1 completed, 1 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Cannabinoid Hyperemesis Syndrome: new trials by email Literature Review of Cannabinoid Hyperemesis Syndrome trials Research Report on Cannabinoid Hyperemesis Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department Olanzapine 10 milligram, Haloperidol - Cannabinoid Hyperemesis Syndrome | Phase 3 | Completed | Mercy Bon Secours Saint Vincent Medical Center | 31 | 2025-11-06 | 2026-10-14 |
| Droperidol on Prevention of Cannabis Hyperemesis Syndrome Droperidol Injectable Product, Diphenhydramine - Cannabis Hyperemesis Syndrome | Phase 3 | Unknown | Mercy Health Ohio | 45 | 2021-12-02 | 2023-01-20 |
Chemically-Induced Disorders (2) · Marijuana Abuse (2) · Mental Disorders (2) · Substance-Related Disorders (2)
Diphenhydramine (1) · Droperidol (1) · Haloperidol (1)
Mercy Bon Secours Saint Vincent Medical Center (1) · Mercy Health Ohio (1)
United States (2)
Todd Bolotin, MD (1)